ERBB2 and hepatocellular carcinoma: Molecular docking of five key active benzoxazinone derivatives with six anti‐HCC core targets (c‐Myc, ESR1, EGFR, HSP90AA1, CCND1, and ERBB2) was performed and the binding affinity are summarized in Table S20.